tickrz reports
Mallinckrodt Plc (MNK)
Healthcare | Drugs
22.27  -0.13%
MNK vs DRUGS SECTOR & S&P 500
VALUATION
MNKSECTORS&P 500
P/E RATIO3.383820.18
EV/EBITDA RATIO6.28121.612.15
P/S RATIO0.726.22.14
P/B RATIO0.427.33.29
QUALITY
RETURN ON EQUITY12.41%15.79%13.65%
RETURN ON CAPITAL27.18%19.38%10.09%
NET MARGIN14.46%14.46%9.76%
DIVIDEND ANALYSIS
DIVIDEND YIELD
0%
PAYOUT RATION/A
3 YR DIVIDEND GROWTHN/A
FINANCIAL STRENGTH
PIOTROSKI F SCORE
6 OUT OF 9
DEBT-TO-EQUITY114%
INTEREST COVERAGE1.4x
CURRENT RATIO1.38
GROWTH
5 YR EPS GROWTH13.48%
5 YR SPS GROWTH10.83%
5 YR BPS GROWTH9.67%
Mallinckrodt Plc News
Lam Research, Mallinckrodt, Texas Instruments, Vishay Intertechnology and Marvell Technology highlighted as Zacks Bull and Bear of the Day
Lam Research, Mallinckrodt, Texas Instruments, Vishay Intertechnology and Marvell Technology highlighted as Zacks Bull and Bear of the Day
December 08, 14:11:02 UTC

Bear of the Day: Mallinckrodt PLC (MNK)
Bear of the Day: Mallinckrodt PLC (MNK)
December 08, 12:00:12 UTC

Mallinckrodt To Present At 36th Annual J.P. Morgan Healthcare Conference
STAINES-UPON-THAMES, England , Dec. 8, 2017 /PRNewswire/ --  Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global specialty pharmaceutical company, will present on Monday, Jan. 8, 2018 , at the 36 ...
December 08, 11:55:00 UTC

Edited Transcript of MNK earnings conference call or presentation 7-Nov-17 1:30pm GMT
Q3 2017 Mallinckrodt Plc Earnings Call
December 06, 21:10:16 UTC

Mallinckrodt is Now Oversold (MNK)
Legendary investor Warren Buffett advises to be fearful when others are greedy and be greedy when others are fearful One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index or RSI which measures momentum on
December 06, 19:08:05 UTC

See what the IHS Markit Score report has to say about Mallinckrodt Plc.
Mallinckrodt Plc NYSE:MNK
December 06, 13:01:54 UTC

Mallinckrodt plc Presents Health Economic Data on Management of Infantile Spasms at American Epilepsy Society Annual Meeting
-- Retrospective Study Showed High Healthcare Resource Use in Patients Prior to Receiving H.P. Acthar® Gel (Repository Corticotropin Injection) for Infantile Spasms -- STAINES-UPON-THAMES, United Kingdom ...
December 04, 14:49:00 UTC

Express Scripts Sells Unit With Ties to a $35,000-a-Vial Drug
Express Scripts Holding Co. is trimming some of its ties to a $35,000-a-vial medicine made by Mallinckrodt Plc by selling a unit that helps patients access some high-priced drugs.
November 27, 17:44:06 UTC

Energy, healthcare & earnings movers in the Trader Blitz
The "Halftime Report" traders take investors through some of the day's biggest movers including: Guess, Gamestop, and HP Enterprise.
November 22, 18:11:00 UTC

Mallinckrodt: We Know It's Sick…and It's Not Getting Better
Shares of Mallinckrodt (MNK) are lower today, following a downgrade from Oppenheimer.  Analyst Derek Archila admits that he was "flat out wrong" about the stock, and thus cut his rating on the stock from Outperform to Perform Wednesday, writing that this thesis that the company could see margin expansion and branded growth isn't likely to happen in the next year and beyond. More from the note:  We don't see material year-over-year Acthar growth returning until 2H18 assuming MNK can manage through the recent payer pushback/patient abandonment issues. After speaking with MNK, we get the sense revised 4Q17 and 2018 Acthar consensus estimates may look high.  What to expect in 2018?
November 22, 15:43:00 UTC

Mallinckrodt In The Red Following Downgrade By Oppenheimer
Mallinckrodt In The Red Following Downgrade By Oppenheimer
November 22, 13:17:00 UTC

Mallinckrodt (MNK) Down 55% Year to Date: What Lies Ahead?
Mallinckrodt plc (MNK)'s stock lost 55% in the year so far due to ongoing investigations and weakness in Acthar and Inomax.
November 20, 21:07:09 UTC

Mallinckrodt plc Presents Health Economic Data on OFIRMEV® (acetaminophen) Injection at ASRA 16th Annual Pain Medicine Meeting
-- Retrospective Analyses Showed IV Acetaminophen was Associated with Shorter Hospital Stay, Decreased Hospitalization Costs Versus Oral Acetaminophen in Postoperative Patients -- STAINES-UPON-THAMES, ...
November 16, 13:20:00 UTC

See what the IHS Markit Score report has to say about Mallinckrodt Plc.
Short interest is high for MNK with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting MNK. The net inflows of $4.18 billion over the last one-month into ETFs that hold MNK are among the lowest of the last year and appear to be slowing.
November 16, 13:02:00 UTC

[$$] Two Lawsuits Hit Express Scripts Unit on Pricing
A securities filing made Tuesday by Express Scripts Holdings (ESRX) disclosed two large lawsuits that claim its subsidiary United Biosource helped drugmakers market their products in violation of antitrust and anti-kickback laws. The allegations in those suits touch on issues that Barron’s covered in a 2015 story that described how UBC’s contracts to promote drugmakers’ high-priced products seemed to conflict with the mission of its pharmacy benefit management parent: that is, to keep a lid on America’s drug bills (“Express Scripts Unit’s Connection to High Priced Specialty Drugs,” November 21, 2015). Other companies also named as defendants in the two suits were Eli Lilly & Co. (LLY) and Mallinckrodt PLC (MNK), as well as the Covance unit of Laboratory Corp. of America Holdings (LH).
November 16, 00:22:00 UTC


Mallinckrodt Plc (MNK)
Healthcare | Drugs
22.27  -0.13%

Lam Research, Mallinckrodt, Texas Instruments, Vishay Intertechnology and Marvell Technology highlighted as Zacks Bull and Bear of the Day
Lam Research, Mallinckrodt, Texas Instruments, Vishay Intertechnology and Marvell Technology highlighted as Zacks Bull and Bear of the Day
December 08, 14:11:02 UTC

Bear of the Day: Mallinckrodt PLC (MNK)
Bear of the Day: Mallinckrodt PLC (MNK)
December 08, 12:00:12 UTC

Mallinckrodt To Present At 36th Annual J.P. Morgan Healthcare Conference
STAINES-UPON-THAMES, England , Dec. 8, 2017 /PRNewswire/ --  Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global specialty pharmaceutical company, will present on Monday, Jan. 8, 2018 , at the 36 ...
December 08, 11:55:00 UTC

Edited Transcript of MNK earnings conference call or presentation 7-Nov-17 1:30pm GMT
Q3 2017 Mallinckrodt Plc Earnings Call
December 06, 21:10:16 UTC

Mallinckrodt is Now Oversold (MNK)
Legendary investor Warren Buffett advises to be fearful when others are greedy and be greedy when others are fearful One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index or RSI which measures momentum on
December 06, 19:08:05 UTC

See what the IHS Markit Score report has to say about Mallinckrodt Plc.
Mallinckrodt Plc NYSE:MNK
December 06, 13:01:54 UTC

Mallinckrodt plc Presents Health Economic Data on Management of Infantile Spasms at American Epilepsy Society Annual Meeting
-- Retrospective Study Showed High Healthcare Resource Use in Patients Prior to Receiving H.P. Acthar® Gel (Repository Corticotropin Injection) for Infantile Spasms -- STAINES-UPON-THAMES, United Kingdom ...
December 04, 14:49:00 UTC

Express Scripts Sells Unit With Ties to a $35,000-a-Vial Drug
Express Scripts Holding Co. is trimming some of its ties to a $35,000-a-vial medicine made by Mallinckrodt Plc by selling a unit that helps patients access some high-priced drugs.
November 27, 17:44:06 UTC

Energy, healthcare & earnings movers in the Trader Blitz
The "Halftime Report" traders take investors through some of the day's biggest movers including: Guess, Gamestop, and HP Enterprise.
November 22, 18:11:00 UTC

Mallinckrodt: We Know It's Sick…and It's Not Getting Better
Shares of Mallinckrodt (MNK) are lower today, following a downgrade from Oppenheimer.  Analyst Derek Archila admits that he was "flat out wrong" about the stock, and thus cut his rating on the stock from Outperform to Perform Wednesday, writing that this thesis that the company could see margin expansion and branded growth isn't likely to happen in the next year and beyond. More from the note:  We don't see material year-over-year Acthar growth returning until 2H18 assuming MNK can manage through the recent payer pushback/patient abandonment issues. After speaking with MNK, we get the sense revised 4Q17 and 2018 Acthar consensus estimates may look high.  What to expect in 2018?
November 22, 15:43:00 UTC

Mallinckrodt In The Red Following Downgrade By Oppenheimer
Mallinckrodt In The Red Following Downgrade By Oppenheimer
November 22, 13:17:00 UTC

Mallinckrodt (MNK) Down 55% Year to Date: What Lies Ahead?
Mallinckrodt plc (MNK)'s stock lost 55% in the year so far due to ongoing investigations and weakness in Acthar and Inomax.
November 20, 21:07:09 UTC

Mallinckrodt plc Presents Health Economic Data on OFIRMEV® (acetaminophen) Injection at ASRA 16th Annual Pain Medicine Meeting
-- Retrospective Analyses Showed IV Acetaminophen was Associated with Shorter Hospital Stay, Decreased Hospitalization Costs Versus Oral Acetaminophen in Postoperative Patients -- STAINES-UPON-THAMES, ...
November 16, 13:20:00 UTC

See what the IHS Markit Score report has to say about Mallinckrodt Plc.
Short interest is high for MNK with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting MNK. The net inflows of $4.18 billion over the last one-month into ETFs that hold MNK are among the lowest of the last year and appear to be slowing.
November 16, 13:02:00 UTC

[$$] Two Lawsuits Hit Express Scripts Unit on Pricing
A securities filing made Tuesday by Express Scripts Holdings (ESRX) disclosed two large lawsuits that claim its subsidiary United Biosource helped drugmakers market their products in violation of antitrust and anti-kickback laws. The allegations in those suits touch on issues that Barron’s covered in a 2015 story that described how UBC’s contracts to promote drugmakers’ high-priced products seemed to conflict with the mission of its pharmacy benefit management parent: that is, to keep a lid on America’s drug bills (“Express Scripts Unit’s Connection to High Priced Specialty Drugs,” November 21, 2015). Other companies also named as defendants in the two suits were Eli Lilly & Co. (LLY) and Mallinckrodt PLC (MNK), as well as the Covance unit of Laboratory Corp. of America Holdings (LH).
November 16, 00:22:00 UTC